In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode they’ll talk about the prevalence of NAFLD and NASH and their clinical and economic burdens.
By the end of this podcast, listeners should be able to:
To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.
This activity is accredited through Sep. 30, 2022.
Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University
Guest: Zobair Younossi, MD, President, Medicine Service Line, Inova Health System
Created by: Knighten Health, LLC
Produced and edited by: Nick Jaworksi
Cover art: THOR Design Studio
Fasiha Kanwal discloses no conflicts.
Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.
Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.
Zobair Younossi has received research funding from or served as a consultant for Gilead Sciences, Intercept, BMS, Novo Nordisk, Viking, Terns, Siemens, Shionogi, AbbVie, Madrigal, Merck, Abbott, Axcella, and Novartis.
American Gastroenterological Association
This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.